by stemedica admin | Apr 20, 2020 | Intellectual Property
SANTA MONICA – April 20, 2020 – A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration for the treatment of severe lung injury due to COVID-19 at the Providence Saint John’s Health Center, Santa Monica,...
by stemedica admin | Aug 13, 2015 | Intellectual Property
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received United States Patent No. 9080184 entitled “Transgenic Therapeutic Stem Cells and Methods for Their Use and Manufacture.” The patent issued on July...
by stemedica admin | Jun 9, 2015 | Intellectual Property
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.” This patent, coupled with the US8105380 patent...
by stemedica admin | Feb 18, 2015 | Intellectual Property
Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the Company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent...
